X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs LUPIN LTD - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES LUPIN LTD PIRAMAL ENTERPRISES/
LUPIN LTD
 
P/E (TTM) x 36.6 19.9 183.6% View Chart
P/BV x 3.0 2.7 112.7% View Chart
Dividend Yield % 0.8 0.9 86.2%  

Financials

 PIRAMAL ENTERPRISES   LUPIN LTD
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
LUPIN LTD
Mar-17
PIRAMAL ENTERPRISES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2,0951,750 119.7%   
Low Rs1,0251,384 74.1%   
Sales per share (Unadj.) Rs492.8387.4 127.2%  
Earnings per share (Unadj.) Rs72.656.6 128.1%  
Cash flow per share (Unadj.) Rs94.776.8 123.2%  
Dividends per share (Unadj.) Rs21.007.50 280.0%  
Dividend yield (eoy) %1.30.5 281.2%  
Book value per share (Unadj.) Rs862.5298.9 288.5%  
Shares outstanding (eoy) m172.56451.58 38.2%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.24.0 78.3%   
Avg P/E ratio x21.527.7 77.7%  
P/CF ratio (eoy) x16.520.4 80.8%  
Price / Book Value ratio x1.85.2 34.5%  
Dividend payout %28.913.2 218.6%   
Avg Mkt Cap Rs m269,194707,513 38.0%   
No. of employees `0004.016.8 23.9%   
Total wages/salary Rs m17,93928,495 63.0%   
Avg. sales/employee Rs Th21,190.310,418.3 203.4%   
Avg. wages/employee Rs Th4,470.11,697.0 263.4%   
Avg. net profit/employee Rs Th3,120.01,523.0 204.9%   
INCOME DATA
Net Sales Rs m85,037174,943 48.6%  
Other income Rs m2,3381,065 219.5%   
Total revenues Rs m87,374176,008 49.6%   
Gross profit Rs m34,99144,931 77.9%  
Depreciation Rs m3,8179,122 41.8%   
Interest Rs m20,3101,525 1,331.5%   
Profit before tax Rs m13,20235,349 37.3%   
Minority Interest Rs m1,699-72 -2,369.6%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2819,785 23.3%   
Profit after tax Rs m12,52025,575 49.0%  
Gross profit margin %41.125.7 160.2%  
Effective tax rate %17.327.7 62.4%   
Net profit margin %14.714.6 100.7%  
BALANCE SHEET DATA
Current assets Rs m87,590119,542 73.3%   
Current liabilities Rs m185,57861,206 303.2%   
Net working cap to sales %-115.233.3 -345.6%  
Current ratio x0.52.0 24.2%  
Inventory Days Days3176 40.8%  
Debtors Days Days4890 52.9%  
Net fixed assets Rs m108,523131,660 82.4%   
Share capital Rs m345903 38.2%   
"Free" reserves Rs m148,481134,073 110.7%   
Net worth Rs m148,826134,976 110.3%   
Long term debt Rs m144,95756,478 256.7%   
Total assets Rs m482,394266,073 181.3%  
Interest coverage x1.724.2 6.8%   
Debt to equity ratio x1.00.4 232.8%  
Sales to assets ratio x0.20.7 26.8%   
Return on assets %6.810.2 66.8%  
Return on equity %8.418.9 44.4%  
Return on capital %12.019.3 62.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00181,885 18.3%   
Fx outflow Rs m5,15021,506 23.9%   
Net fx Rs m9,85160,378 16.3%   
CASH FLOW
From Operations Rs m-100,39341,148 -244.0%  
From Investments Rs m-24,202-25,287 95.7%  
From Financial Activity Rs m135,7054,332 3,132.8%  
Net Cashflow Rs m11,11020,193 55.0%  

Share Holding

Indian Promoters % 52.9 46.6 113.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.0 11.3 35.4%  
FIIs % 26.6 31.9 83.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.1 163.4%  
Shareholders   93,274 98,259 94.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 23, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - FRESENIUS KABI ONCO. COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS